Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Exosome-based therapy for epilepsy: a systematic review and meta-analysis of preclinical studies

Yang Y., Wu Y., Si J., Zhang G., Dong L., Liu H.

Meta-analysis on Neuroinflammation, published in Front Neurosci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Front Neurosci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42222371
PMCID
PMC13219301
DOI
10.3389/fnins.2026.1824183

Abstract (original English)

Objective This study aims to quantitatively assess the efficacy of exosome therapy for epilepsy through a systematic review and meta-analysis of preclinical animal experiments. We seek to clarify its overall effects on seizure reduction, cognitive function preservation, and neuroinflammation suppression. Methods A systematic search was conducted across four English-language and four Chinese databases to include epilepsy animal studies. Continuous outcomes were synthesized using standardized mean differences (SMD) and 95% confidence intervals (CI), with fixed or random effects models selected based on heterogeneity. Results A total of eight preclinical studies were included. The overall meta-analysis revealed that exosome treatment significantly reduced the duration of seizures (SMD = -2.30, 95% CI -4.24 to -0.36), decreased the frequency of spontaneous recurrent seizures (SMD = -1.38, 95% CI -2.17 to -0.58), and prolonged the seizure latency (SMD = 1.49, 95% CI 0.08-2.90). In terms of cognitive function, exosomes significantly shortened the escape latency in the Morris water maze (SMD = -1.38, 95% CI -2.17 to -0.58), increased the percentage of time spent in the target quadrant (SMD = 3.69, 95% CI 0.30-7.08), and enhanced the number of platform crossings (SMD = 1.41, 95% CI 0.60-2.21), with no significant changes in swimming speed. Neuropathological analysis indicated that exos

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research